迪哲医药(688192) - 2023 Q1 - 季度财报

Financial Performance - The company's net profit attributable to shareholders for Q1 2023 was -239,523,659.32 RMB, with a basic and diluted earnings per share of -0.59 RMB[4] - Net loss for Q1 2023 was ¥239,523,659.32, compared to a net loss of ¥181,726,770.92 in Q1 2022, indicating a worsening of approximately 31.8%[32] - Total comprehensive loss for Q1 2023 was ¥239,523,659.32, which is the same as the net loss, indicating no other comprehensive income for the period[33] - Basic and diluted earnings per share for Q1 2023 were both -¥0.59, compared to -¥0.45 in Q1 2022[33] Assets and Liabilities - Total assets decreased by 10.03% year-over-year, amounting to 1,873,081,804.84 RMB[5] - Total liabilities decreased from RMB 323,427,016.13 to RMB 302,334,918.64, a decline of approximately 6.5%[46] - Owner's equity decreased from RMB 1,758,481,039.11 to RMB 1,570,746,886.20, a reduction of about 10.7%[46] - Current assets decreased from RMB 1,473,178,113.01 to RMB 1,270,749,566.73, representing a reduction of about 13.7%[45] - Non-current assets totaled RMB 602,332,238.11, slightly down from RMB 608,729,942.23, a decrease of around 1.6%[45] Cash Flow - The cash flow from operating activities was -203,213,936.04 RMB, indicating a negative cash flow situation[4] - The net cash outflow from operating activities for Q1 2023 was ¥203,213,936.04, compared to ¥172,890,065.46 in Q1 2022, reflecting an increase in cash burn[35] - Cash inflow from operating activities totaled RMB 11,119,984.71, an increase from RMB 8,432,318.55 in the previous period[53] - Cash and cash equivalents at the end of Q1 2023 were ¥85,008,536.02, down from ¥235,264,870.21 at the end of Q1 2022, a decrease of approximately 63.8%[35] - Investment activities generated a net cash inflow of ¥176,813,618.24 in Q1 2023, compared to ¥63,199,017.79 in Q1 2022, indicating a significant improvement in investment cash flow[35] Research and Development - R&D investment totaled 156,614,796.50 RMB, representing a 7.00% decrease compared to the previous year[4] - R&D expenses for Q1 2023 were ¥156,614,796.50, a decrease of about 7% compared to ¥168,406,675.29 in Q1 2022[30] - The company has submitted a new drug application for Shuwotini for the treatment of advanced or metastatic non-small cell lung cancer, which has been accepted for priority review[12] Expenses - The company reported a significant increase in management expenses by 136.70% due to new equity incentive costs[7] - The company reported a significant increase in sales expenses to ¥35,756,837.80 in Q1 2023, although the exact figure for Q1 2022 was not provided[30] - The company experienced a decrease in financial expenses to ¥912,666.36 in Q1 2023 from ¥1,390,542.74 in Q1 2022, a reduction of approximately 34.4%[30] Government Support and Compliance - The company received government subsidies amounting to 4,003,000.00 RMB during the reporting period[19] - The company is focused on ensuring compliance with tax and accounting regulations affecting current profit and loss adjustments[58] - The company has not engaged in any financing or securities lending activities with major shareholders[41] - The company is not applying new accounting standards for the current fiscal year[54] Other Financial Information - The total non-recurring profit and loss amounted to 11,210,672.55[58] - The financial assets, trading financial liabilities, and derivative financial liabilities contributed to the investment income[58] - The company conducted impairment tests on receivables and contract assets, resulting in a reversal of provisions[58] - The company reported gains from entrusted loans[58] - The fair value changes of investment properties measured at fair value resulted in profit or loss[58] - The company recognized income from entrusted management fees[58] - The impact of income tax on the current profit and loss was deducted[58] - The minority interest impact (after tax) was accounted for in the total[58] - The company is exploring new strategies for market expansion and product development[58]